GRAIL emphasizes cancer screening during Men's Health Month
Prostate, lung, and colorectal cancers account for nearly 50% of male diagnoses, with stage impacting outcomes.
See the latest news and media coverage for GRAIL. We track all announcements, press releases, and industry mentions in real time, all in one place.
Multi-cancer early detection company
grail.comLast updated
In short: GRAIL completed its spin-off from Illumina and transitioned to a standalone public company while facing a securities fraud class action lawsuit.
Prostate, lung, and colorectal cancers account for nearly 50% of male diagnoses, with stage impacting outcomes.
Ann's participation in the NHS-Galleri trial led to early diagnosis of stage III bowel cancer, with 82% sensitivity.
The episode features Dr. Scout from the National LGBT Cancer Network addressing barriers to screening and care.
Quoting Dr. Nima Nabavizadeh on multi-cancer early detection potential.
Deadline Alert: Grail, Inc. (GRAL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitGlancy Prongay Wolke ...
GRAIL (NASDAQ:GRAL) said new data presented at the American Society of Clinical Oncology annual meeting showed its Galleri multi-cancer early detection blood test can identify...
"We're reiterating still the same guidance, not updating it" and "You got a 10% range there" (Chief Financial Officer Freidin). "We expect our growth for...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or...
Track GRAIL and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to GRAIL and other trending companies.